DISHMAN GROUP successful trial production for New Manufacturing Plant in Shanghai, China

May 11, 2010

Dishman Group has successfully completed the trial production of its new China facility. The trial was done during the second week of May 2010.

Dishman Group has successfully completed the trial production of its new China facility. The trial was done during the second week of May 2010. Consequently, Dishman plans to inaugurate the new multi-product cGMP facility at the beginning of July 2010. Located in the Shanghai Chemical Industrial Park, and only 45 minutes from Shanghai Pudong International airport, the facility will be the first one the Indian manufacturer opens in China.

With a capital investment of US $18M, the Shanghai site includes a production plant, a warehouse, its own dedicated on-site utilities and administrative/quality control offices. The production unit is arranged in 4 segregated suites, with capability to interlink suites if necessary for specific processes. The raw materials warehouse and finished products warehouse is equipped with right HVAC systems fully pressure controlled to avoid cross contamination. The utilities systems are designed to be outside the chemical handling areas in order to facilitate the cleaning process.

It is expected that most of the products will be in support of the worldwide growing demand from pharmaceutical companies for large volume Active Pharmaceutical Ingredients (APIs). The facility’s large-scale capacity (10 reactors with total capacity from 2,500 L to 8,000 L) will be able to produce multi-tonne quantities with an inherent flexibility to address most API challenges.

Dishman places a focus on safety and security, with an emphasis on risk management strategy, which provides redundancy of supply in multiple Asian sites and countries and also provides ease of Asian collaboration. “Additional locations and infrastructure provide secure options that maximize speed, flexibility and cost advantages for customers with the same safety and quality standards globally,” said Jay Vyas, managing director, Dishman Pharmaceuticals and Chemicals Ltd.